BAG3 GENE THERAPY OPTIMIZATION

MX434284BActive Publication Date: 2026-05-19TEMPLE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
MX · MX
Patent Type
Patents
Current Assignee / Owner
TEMPLE UNIV
Filing Date
2020-12-08
Publication Date
2026-05-19

AI Technical Summary

Technical Problem

There is a higher incidence and younger age of onset of ischemic and non-ischemic dilated cardiomyopathy (DCM) in individuals of African descent, which is attributed to specific genetic variants of the BAG3 gene, leading to adverse outcomes in cardiac diseases such as heart failure.

Method used

Identification and modulation of BAG3 genetic variants, particularly in-frame insertions like p.Ala160dup, to normalize BAG3 expression and function, using agents that target BAG3 molecules in target cells or tissues, and administering therapeutically effective amounts of agents that modulate BAG3 levels.

Benefits of technology

This approach improves cardiac outcomes by predicting and addressing the negative influence of BAG3 genetic variants, potentially reducing the risk of death or hospitalization from heart failure in patients with these variants.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The identification of genetic variants of BAG3 (Bcl2-associated anthanogen 3) were associated with the prevalence of ischemic or non-ischemic dilated cardiomyopathy (DCM) and DCM outcomes in people of African descent.
Need to check novelty before this filing date? Find Prior Art